ADIPOQ and metabolic syndrome: Novel clinical (adiponectin, leptin, and adiponectin-to-leptin ratio), molecular, and omic biomarkers have been inventoried within HBM4EU and proposed as biological indicators that could help to identify the role of PFAS in metabolic syndrome [59].